SCHEMBL16694764

SCHEMBL16694764

Cc1cc(C)cc(-c2cncc(N)c2N2CCC(NC(=O)O)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ SSTR2 P30874 19/20 0.57
▸ KCNH2 Q12809 14/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16694749 0.87 SSTR2 (0.50) SSTR2KCNH2
SCHEMBL16694762 0.86 SSTR2 (0.54) SSTR2KCNH2
SCHEMBL16695046 0.82 SSTR2 (0.78) SSTR2KCNH2
SCHEMBL16694846 0.79 CYP3A4 (0.39) SSTR2KCNH2
SCHEMBL16694393 0.79 SSTR2 (0.60) SSTR2KCNH2
SCHEMBL16694668 0.79 SSTR2 (0.51) SSTR2KCNH2
SCHEMBL22976573 0.78 SSTR2 (0.47) SSTR2KCNH2
SCHEMBL22976575 0.78 SSTR2 (0.47) SSTR2KCNH2
SCHEMBL16694750 0.78 SSTR2 (0.75) SSTR2KCNH2
SCHEMBL16694789 0.77 SSTR2 (0.51) SSTR2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194775-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO., LTD. (JP) 2018-07-12 — — US disclosed
US-9975904-B2 Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes ONO PHARMACEUTICAL CO., LTD. (JP) 2018-05-22 — — US disclosed
US-20170183359-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO., LTD. (JP) 2017-06-29 — — US disclosed
US-9630976-B2 Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes ONO PHARMACEUTICAL CO., LTD. (JP) 2017-04-25 — — US disclosed
US-20150232478-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO., LTD. (JP) 2015-08-20 — — US disclosed
EP-2871179-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO Pharmaceutical Co., Ltd. (JP) 2015-05-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183359-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES SSTR2, SSTR1, SSTR3 SSTR2 1/4885KCNH2 3384/4885
US-20150232478-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES SSTR2, SSTR1, SSTR3 SSTR2 1/4885KCNH2 3149/4885
US-20180194775-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES SSTR2, SSTR1, SSTR3 SSTR2 1/4885KCNH2 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback